GENMAB A/S -SP ADR
GMABNASDAQTrading Snapshot
- Day Range
- $35.00 – $36.01
- 52-Week Range
- $23.62 – $35.70
- Volume
- $4.02B
- Avg Volume
- $4.49B
- Shares Outstanding
- 613.9M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.72B
- Last Q Revenue
- $1.16B
- P/E Ratio
- 27.4
- P/S Ratio
- 2.2x
- EPS (TTM)
- $1.29
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.8%
Why Investors Own GMAB
- ✓High-growth profile — revenue up +13.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GENMAB A/S -SP ADR
GMAB
StockOtter · stockotter.spaceAbout GENMAB A/S -SP ADR
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
GENMAB A/S -SP ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift GMAB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
GENMAB A/S -SP ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.